Navigation Links
Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQ's Minimum Bid Price Rule
Date:10/23/2008

- Company Now Has Until April 27, 2009 to Regain Compliance with $1.00

Minimum Bid Price Rule -

TUSTIN, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today announced that it has received a letter from NASDAQ that provides Peregrine with additional time to regain compliance with the minimum bid price rule. Peregrine now has until April 27, 2009 to regain compliance with NASDAQ's $1.00 minimum bid price rule in order to remain listed on The Nasdaq Stock Market. This extension was granted as part of NASDAQ's recently announced temporary suspension of the minimum bid price and market value requirements for all NASDAQ-listed companies.

As previously announced, Peregrine received a letter from NASDAQ on September 16, 2008 informing the company that the Nasdaq Listing Qualifications Panel had granted Peregrine's request to remain listed on NASDAQ, subject to the condition that on or before January 20, 2009, Peregrine must have evidenced a closing bid price of $1.00 or more for a minimum of ten prior consecutive trading days. This deadline is now extended until April 27, 2009.

Peregrine also announced that at the company's Annual Meeting of Stockholders held on October 21, 2008, stockholders approved a proposal that provides the company's Board of Directors with discretionary authority over the course of the next year to implement a reverse split of the issued and outstanding shares of Peregrine's common stock as a potential remedy to regain compliance with the $1.00 minimum bid price rule.

About Peregrine Pharmaceuti
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
3. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
4. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
5. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
6. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
7. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
8. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
9. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
10. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... 2014 The Asia-Pacific Bio-based Advanced ... the bio-based advanced phase change material market in ... Browse through the TOC of the Asia-Pacific Bio-based ... an idea of the in-depth analysis provided. This ... the Asia-Pacific bio-based advanced phase change material market, ...
(Date:10/18/2014)... 2014 The Asia-Pacific hardware encryption display ... Asia-Pacific with analysis and forecast of revenue. This market ... to reach $51,362.6 million by 2018, at a CAGR ... the TOC of the Asia-Pacific hardware encryption market report, ... This also provides a glimpse of the segmentation of ...
(Date:10/18/2014)... New York, NY (PRWEB) October 18, 2014 ... at a healthy rate in the five years to ... by several federal renewable energy tax credits that encouraged ... states have enacted renewable portfolio standards (RPSs), which require ... a percentage of their total energy portfolio. Increased campaigning ...
(Date:10/18/2014)... 2014 The “Global Diagnostic Electrocardiograph ... by End-user (Hospitals, Home/Ambulatory, Research Center, Physician Office, ... -Global Forecast to 2020” provides a detailed overview ... market trends, and strategies impacting the global diagnostic ... of the revenue and share analysis. , The ...
Breaking Biology Technology:The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 4The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 2Biomass Power in the US Industry Market Research Report from IBISWorld Has Been Updated 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 2The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 4The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 5
... SAN DIEGO, Feb. 26 Ambrx Inc. today ... as Senior Vice President,for Clinical Research and Development., ... spanning nearly two,decades at Procter & Gamble Pharmaceuticals. ... for Discovery, Early Development and Product,Development where he ...
... NATICK, Mass., Feb. 26 Boston Scientific,Corporation (NYSE: ... Ph.D.,will be joining the Company,s Clinical Sciences organization effective,March ... and Associate Chief Medical,Officer, sitting on the Clinical Leadership ... Dr. Donald S. Baim, M.D. In his new role,Dr. ...
... Feb. 26 BioStorage Technologies, Inc.,(BST), announces the ... the company,s European operations in Griesheim, Germany. Hoffer,joins ... in the fields of,clinical pharmacology and toxicology. In ... M. Saponaro, Chief Operating Officer for BST, and ...
Cached Biology Technology:Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development 2Boston Scientific Announces Addition to Clinical Sciences Organization 2Boston Scientific Announces Addition to Clinical Sciences Organization 3Boston Scientific Announces Addition to Clinical Sciences Organization 4BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations 2
(Date:10/14/2014)... ATHENS, Ohio (Oct. 14, 2014)—It,s been millions of years ... but a team led by Ohio University scientists is ... to model airflow through dinosaur snouts. The research has ... not only breathe but to enhance the sense of ... pretty ,nosy, animals," said Ohio University doctoral student Jason ...
(Date:10/14/2014)... A Mount Sinai-led research team has discovered a new kind ... or a cell that lines liver blood vessels, according to ... Reports . The existence of such a cell type contradicts ... the embryo, and may hold clues to origins of, and ... develop from a single cell into a complex being made ...
(Date:10/14/2014)... team of scientists led by researchers at the ... University of Miami Miller School of Medicine (UMMSM) ... pathway underlying bipolar (manic depressive) disorder, a breakthrough ... bipolar affective disorder, as well as depression and ... published online this week in Nature Molecular ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... (April 19, 2010) Virginia Commonwealth University researchers have ... key role in the development of liver cancer. Levels ... than 90 percent of patients with the disease compared ... Virginia Commonwealth University Massey Cancer Center and the VCU ...
... Md. (April 19, 2010) Chesapeake Biological Laboratory Director ... of Maryland Center for Environmental Science with its President,s ... informing policymakers and the public about the environmental impacts ... Dr. Palmer seeks to expand the impact of her ...
... metals or semiconductors to soft organic or biological products. Picture ... Mother Nature. The applications in medicine and manufacturing ... of nanoscience at The Florida State University. How ... chip" that can diagnose illness? That and much more are ...
Cached Biology News:Researchers identify new gene involved in the development of liver cancer 2UMCES ecologist Margaret Palmer recognized for promoting the role of science in public policy 2Bionanotechnology has new face, world-class future at Florida State 2Bionanotechnology has new face, world-class future at Florida State 3
2ndGen Predilute antibody for staining tissue sections. Optimized for use with Zymeds Histostain-PLUS, NBA, HistoST5050, and Cap-Plus IHC Kits.Labeling: ASR...
Sprague Dawley rats, 7-8 weeks of age, mixed gender; collected by exsanguination in Alsever's solution at 1:2 dilution...
... The S.c. EasyComp Transformation Kit ... transformation-competent Saccharomyces cerevisiae cells. Advantages over ... spheroplast formation or LiCl methods include:- Cells ... than 30 minutes - Competent cell preparation ...
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
Biology Products: